Royal Bank of Canada Purchases 115,939 Shares of Glaukos Corporation $GKOS

Royal Bank of Canada boosted its stake in Glaukos Corporation (NYSE:GKOS - Free Report) by 103.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,249 shares of the medical instruments supplier's stock after purchasing an additional 115,939 shares during the period. Royal Bank of Canada owned about 0.40% of Glaukos worth $22,464,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bessemer Group Inc. grew its holdings in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 158 shares during the period. Whipplewood Advisors LLC grew its holdings in Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. grew its holdings in Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc grew its holdings in Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 327 shares during the period. Finally, CoreCap Advisors LLC grew its holdings in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after acquiring an additional 200 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GKOS has been the topic of a number of research analyst reports. BTIG Research reissued a "buy" rating and set a $118.00 price objective on shares of Glaukos in a research report on Wednesday. UBS Group increased their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Mizuho set a $130.00 price objective on shares of Glaukos in a research report on Thursday, July 31st. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Zacks Research cut shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and an average target price of $124.83.

Glaukos Stock Performance

Shares of GKOS stock traded down $3.20 during trading hours on Wednesday, hitting $87.72. 866,980 shares of the company were exchanged, compared to its average volume of 636,688. The firm has a fifty day simple moving average of $94.22 and a 200 day simple moving average of $96.34. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -53.16 and a beta of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter last year, the business posted ($0.52) EPS. Glaukos's quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.